Cogent Biosciences (COGT) Competitors $12.08 -0.29 (-2.34%) Closing price 04:00 PM EasternExtended Trading$12.32 +0.24 (+2.03%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. ABVX, MRUS, CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, and ACLXShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx Abivax (NASDAQ:ABVX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends. Which has more risk & volatility, ABVX or COGT? Abivax has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Is ABVX or COGT more profitable? Abivax's return on equity of 0.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Cogent Biosciences N/A -223.82%-89.44% Do institutionals and insiders hold more shares of ABVX or COGT? 47.9% of Abivax shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate ABVX or COGT? Abivax currently has a consensus target price of $92.33, suggesting a potential upside of 13.10%. Cogent Biosciences has a consensus target price of $19.00, suggesting a potential upside of 57.28%. Given Cogent Biosciences' higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Does the media prefer ABVX or COGT? In the previous week, Cogent Biosciences had 2 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Cogent Biosciences and 7 mentions for Abivax. Abivax's average media sentiment score of 1.56 beat Cogent Biosciences' score of 1.05 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ABVX or COGT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/ACogent BiosciencesN/AN/A-$255.86M-$1.78-6.79 SummaryAbivax beats Cogent Biosciences on 7 of the 10 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-6.7921.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book29.468.0710.026.67Net Income-$255.86M-$54.08M$3.27B$265.59M7 Day Performance2.63%2.26%3.17%3.42%1 Month Performance-0.08%3.42%4.34%1.09%1 Year Performance16.83%18.61%44.11%23.85% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences3.5177 of 5 stars$12.08-2.3%$19.00+57.3%+24.2%$1.38BN/A-6.7980News CoveragePositive NewsAnalyst ForecastABVXAbivax2.7265 of 5 stars$70.01-0.6%$92.33+31.9%+564.1%$5.32BN/A0.0061News CoveragePositive NewsAnalyst RevisionMRUSMerus2.3278 of 5 stars$66.00-1.9%$88.50+34.1%+26.9%$5.09B$56.23M-12.0037News CoveragePositive NewsAnalyst ForecastCYTKCytokinetics3.7387 of 5 stars$38.95+0.7%$71.58+83.8%-32.3%$4.63B$18.47M-7.64250News CoveragePositive NewsVKTXViking Therapeutics3.8982 of 5 stars$42.09+5.1%$86.92+106.5%-56.7%$4.50BN/A-27.5120TGTXTG Therapeutics4.4007 of 5 stars$27.73-1.2%$46.25+66.8%+23.6%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7119 of 5 stars$146.30-2.6%$210.75+44.1%-25.5%$4.35B$290.52M29.74210ACADACADIA Pharmaceuticals4.0332 of 5 stars$25.06-1.1%$28.88+15.2%+68.7%$4.27B$957.80M18.84510Positive NewsPCVXVaxcyte2.389 of 5 stars$32.09-1.9%$136.50+325.4%-61.2%$4.25BN/A-7.81160Positive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600Gap UpACLXArcellx2.1227 of 5 stars$71.82-3.1%$114.31+59.2%-2.2%$4.11B$107.94M-21.0080News CoveragePositive News Related Companies and Tools Related Companies Abivax Alternatives Merus Alternatives Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access